Is Cervarix a Good HPV Vaccine Option?

December 18, 2018

Though at first glance Cervarix may not appear to be as great as an option for protecting against sexually transmitted HPV infections as Gardasil or even Gardasil 9, it is really quite a reasonable vaccine choice. Despite having been designed to protect against only both strains of high risk HPV (16 and 18) who are most often associated with cervical cancer (at least Caucasian women), in comparison with the other vaccines that target 4 or 9 strains, several studies have provided evidence indicating that Cervarix is actually capable of providing protection against a wide range of oncogenic HPV strains, including, potentially, HPV 31, 33, 35, 45, 52, and 58.

But, unlike Garadsil, it’s unlikely to protect against any of the lower risk strains that are associated with genital warts.

Cervarix is not alone in its ability to offer cross-protection against other HPV strains. Gardasil also seems to have some capability to give cross-protection from a variety of kinds of HPV, but evidence to date, although inconsistent, indicates that the extent of cross-protection might not be as great as it is for Cervarix. In addition, a few of the researchers comparing the capability of the two vaccines to protect against a variety of HPV strains have found evidence indicating that protection from Cervarix may survive more than protection induced by Gardasil.

Simply speaking, the sum total of this evidence suggests that either HPV vaccine option is a great one… and the two vaccines are likely similarly economical. The most important advantage of Gardasil is its capacity to protect against genital warts in addition to various types of cancer.

The main benefit of Cervarix is that it might offer stronger and longer protection against a variety of cancerous breeds.

Oh, and there’s another possible benefit of Cervarix over Gardasil, at least for a small population of the populace. In late 2013, the European Commission declared a reduced dosing schedule of two shots, rather than three, for girls aged 9 to 14.

The 2-dose schedule hasn’t yet been accepted in the USA, but if and when it is, this could be a powerful motivator for some people to choose vaccination with Cervarix over vaccination with Gardasil shot. If you’re somebody who hates injections, or in case you have financial or other logistic concerns about vaccination, being finished after two shots could be a good deal more attractive than having to return for shot number three.